Sign in Create account

Mercury Laboratories Limited

Healthcare · Pharmaceuticals & Biotechnology

BSE: 538964
₹750.00
▼ -10.00 (-1.32%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
51/100
Moderate
Valuation
66/100
Fairly Valued
Momentum
46/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹90 Cr
PE (TTM)
21.6
Industry median 36.1 (152 companies)
Price to Book
1.5
PEG (TTM)
2.1
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-16.8
Free Cash Flow
₹1 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-69.23%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
28.74%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-3.65%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-16.35%
as of Dec. 31, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-11.98%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
3.85
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.13
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
11.48
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
1.87%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
3.23%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
8.14%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
6.25%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
10.66%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
8.51%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.13)
  • No Return on equity is 15% or more (8.5%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.3%
Low 750.0000 · High 785.0000
1W return
-7.4%
Low 750.0000 · High 833.0000
1M return
-2.3%
Low 750.0000 · High 884.0000
52W return
-16.8%
Low 745.0000 · High 884.0000
Lifetime High ₹1275.7000 (Jan. 4, 2024)
Lifetime Low ₹32.4900 (Feb. 26, 2015)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
776.7
10D
785.0
20D
789.5
50D
815.6
100D
846.0
200D
892.7

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
98.7%
Month avg. delivery
92.5%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

761.67
Pivot
First resistance773.33
Second resistance796.67
Third resistance808.33
First support738.33
Second support726.67
Third support703.33
Day RSI38.6
Day MFI49.6
Day MACD-8.41
Day MACD signal-9.13

Beta

1M1.60
3M0.99
1Y0.99
3Y0.41

Price change analysis

↓ -2.3%
Over 1 Month
LowHigh
750.00884.00
↓ -16.8%
Over 3 Months
LowHigh
745.00884.00
↓ -16.8%
Over 6 Months
LowHigh
745.00884.00
↓ -16.8%
Over 1 Year
LowHigh
745.00884.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 21.6 (own history: 17.7–34.4)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹16 Cr
Net profit (June 30, 2026)
₹0 Cr
Basic EPS (June 30, 2026)
₹2.4800

Ranks #143 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter73.66%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 73.66% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 2 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
29 May 2023 SHAH SHARAD KANAYALAL Bulk Buy 8,100 953.6000 BSE
29 May 2023 KETAN BABULAL SHAH Bulk Sell 9,630 953.6500 BSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 3.5000 — —

Corporate Announcements

All 4 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 Company Update Mercury Laboratories Ltd - 538964 - Announcement under Regulation 30 (LODR)-Change in Directorate
30 Sep 2026 AGM/EGM Mercury Laboratories Ltd - 538964 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
28 Sep 2026 AGM/EGM Mercury Laboratories Ltd - 538964 - Shareholder Meeting / Postal Ballot-Outcome of AGM
25 Sep 2026 Insider Trading / SAST Mercury Laboratories Ltd - 538964 - Closure of Trading Window

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.13)
  • Comfortable interest coverage (11.5x)

Weaknesses

  • Low Return on Equity (8.5%)
  • Thin net profit margin (1.9%)
  • Declining revenue YoY (-12.0%)
  • Declining profit YoY (-16.3%)

Opportunities

Data unavailable.

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Mercury Laboratories Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.